All In Biotech

Drug Trial Radar · NCT00849030

ATAC - Arimidex, Tamoxifen Alone or in Combination

A Randomised, Double Blind Trial Comparing Arimidex Alone With Nolvadex Alone With Arimidex and Nolvadex in Combination, as Adjuvant Treatment in Post-Menopausal Women With Breast Cancer

Last checked: Nov 19, 2026Latest source record: Jun 6, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 9,358 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

9,358

Actual

Start

Jul 1996

Primary completion

Jun 2001

Study completion Apr 2010

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Feb 23, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Female only, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to test whether Arimidex alone or in combination with Tamoxifen is beneficial in the treatment of breast cancer.

Conditions

  • Breast Cancer

Interventions

  • Anastozole (Arimidex)Drug

    1mg, orally, once daily

  • Tamoxifen (Nolvadex)Drug

    20mg, orally, once daily

  • Anastozole (Arimidex) placeboDrug

    1mg, orally, once daily

  • Tamoxifen (Nolvadex) placeboDrug

    20mg, orally, once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to recurrence of breast cancerTime frame: Earliest of local or distant recurrence, new primary breast cancer, or death
  2. Safety and side effectsTime frame: Earliest of local or distant recurrence, new primary breast cancer, or death

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.